Tonelli, Francesca

A pathway for Parkinson’s Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain

Dhekne, H. S., Yanatori, I., Gomez, R. C., Tonelli, F., Diez, F., Schüle, B., Steger, M., Alessi, D. R., & Pfeffer, S. R. (2018) · eLife

Parkinson's Disease Mechanisms and TreatmentsGenetic and Kidney Cyst Diseases

Cited by 240

Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding

Kalogeropulou, A. F., Purlyte, E., Tonelli, F., Lange, S. M., Wightman, M., Prescott, A. R., Padmanabhan, S., Sammler, E., & Alessi, D. R. (2022) · Biochemical Journal

Parkinson's Disease Mechanisms and TreatmentsProtein Kinase Regulation and GTPase Signaling

Cited by 129

RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses

Gustavsson, E. K., Follett, J., Trinh, J., Barodia, S. K., Real, R., Liu, Z., Grant-Peters, M., Fox, J. D., Appel-Cresswell, S., Stoessl, A. J., et al. (2024) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 114

Structural basis of human LRRK2 membrane recruitment and activation

Zhu, H., Tonelli, F., Alessi, D. R., & Sun, J. (2022) · Science

Parkinson's Disease Mechanisms and TreatmentsProtein Kinase Regulation and GTPase Signaling

Cited by 108

Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain

Khan, S. S., Sobu, Y., Dhekne, H. S., Tonelli, F., Berndsen, K., Alessi, D. R., & Pfeffer, S. R. (2021) · eLife

Parkinson's Disease Mechanisms and TreatmentsGenetic and Kidney Cyst Diseases

Cited by 93

Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson’s disease-linked LRRK2 kinase

Dhekne, H. S., Tonelli, F., Yeshaw, W. M., Chiang, C. Y., Limouse, C., Jaimon, E., Purlyte, E., Alessi, D. R., & Pfeffer, S. R. (2023) · eLife

Parkinson's Disease Mechanisms and TreatmentsCellular transport and secretion

Cited by 76

Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson’s disease

Khan, S. S., Jaimon, E., Lin, Y.-E., Nikoloff, J., Tonelli, F., Alessi, D. R., & Pfeffer, S. R. (2024) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsGenetic and Kidney Cyst Diseases

Cited by 61

Parkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B

Pal, P., Taylor, M., Lam, P. Y., Tonelli, F., Hecht, C. A., Lis, P., Nirujogi, R. S., Phung, T. K., Yeshaw, W. M., Jaimon, E., et al. (2023) · Science Advances

Parkinson's Disease Mechanisms and TreatmentsCellular transport and secretion

Cited by 36

Pathogenic LRRK2 mutations cause loss of primary cilia and Neurturin in striatal parvalbumin interneurons

Lin, Y.-E., Jaimon, E., Tonelli, F., & Pfeffer, S. R. (2025) · Life Science Alliance

Parkinson's Disease Mechanisms and TreatmentsGenetic and Kidney Cyst Diseases

Cited by 16